Monte Rosa Therapeutics, Inc.
GLUENasdaq
$24.56
↑ +6.0%Jul 17 close · end-of-day
Price
1Y↑ +337.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.5B
Enterprise Value
$2.3B
P/E
—
P/S
57.1
P/B
4.7
EV/EBITDA
—
PEG
—
FCF Yield
-0.8%
Dividend Yield
—
Revenue (TTM)
$43.0M
Net Income (TTM)
-$130.0M
Free Cash Flow (TTM)
-$19.7M
Gross Margin
—
Operating Margin
-345.2%
Net Margin
-302.6%
ROE
-24.9%
ROIC
-32.4%
Debt / Equity
—
Net Cash
$159.9M
Return 1Y
+316.3%
Company profile
Monte Rosa Therapeutics, Inc. engages in the development of novel small molecule precision medicines. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers.
- CEO
- Markus Warmuth
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- Massachusetts
- Website
- monterosatx.com
Management & directors
- Warmuth MarkusPresident & CEO
- Champoux JenniferChief Operating Officer
- Townson SharonChief Scientific Officer
- Janku FilipChief Medical Officer
- Nickson PhilipChief Business & Legal Officer
- Bowen MatthewPrincipal Accounting Officer
- Dunn EdmundPrincipal Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
GLUE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$4.2M↓ -95.0%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $75.6M | $123.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$28.0M | -$72.9M | -$112.4M | -$143.3M | -$81.1M | -$54.2M |
| Net income | -$35.9M | -$74.0M | -$108.5M | -$135.4M | -$72.7M | -$38.6M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$23.1M | -$59.4M | -$92.5M | -$43.8M | $42.0M | -$22.8M |
| Free cash flow | -$26.4M | -$69.1M | -$105.4M | -$62.8M | $38.0M | -$27.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -107.3% | -43.8% |
| Net margin | — | — | — | — | -96.1% | -31.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7M | $9.2M | $60.6M | $84.9M | $23.2M | $12.8M | $2.8M | $4.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$32.6M | -$26.5M | $13.0M | $44.0M | -$15.6M | -$33.0M | -$49.7M | -$50.0M |
| Net income | -$30.3M | -$23.9M | $13.4M | $46.9M | -$12.3M | -$27.1M | -$46.1M | -$44.5M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$27.8M | -$21.0M | $128.9M | -$45.5M | -$34.7M | $100.4M | -$43.0M | -$37.4M |
| Free cash flow | -$29.8M | -$21.4M | $128.7M | -$47.1M | -$36.4M | $99.8M | -$43.8M | -$39.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -695.3% | -287.8% | 21.4% | 51.9% | -67.1% | -258.3% | -1787.7% | -1188.5% |
| Net margin | -645.6% | -258.9% | 22.2% | 55.2% | -53.0% | -212.1% | -1658.0% | -1057.1% |
Company news
Jul 2, 2026
Jun 29, 2026
Jun 3, 2026
May 20, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-16 | Warmuth Markus· President & CEO | Sale | 9,500 | $23.18 | $220,218.55 | filing |
| 2026-07-15 | Champoux Jennifer· Chief Operating Officer | Sale | 4,351 | $23.38 | $101,729.86 | filing |
| 2026-07-15 | Champoux Jennifer· Chief Operating Officer | Option exercise | 4,351 | $3.98 | $17,316.98 | filing |
| 2026-07-06 | Townson Sharon· Chief Scientific Officer | Sale | 5,600 | $23.25 | $130,197.20 | filing |
| 2026-07-06 | Townson Sharon· Chief Scientific Officer | Option exercise | 6,000 | $6.14 | $36,840.00 | filing |
| 2026-07-06 | Townson Sharon· Chief Scientific Officer | Sale | 400 | $24.13 | $9,652.00 | filing |
| 2026-07-01 | Behbahani Ali | J | 15,000 | $0.00 | $0.00 | filing |
| 2026-07-01 | Behbahani Ali | J | 1,000,000 | $0.00 | $0.00 | filing |
| 2026-07-01 | Behbahani Ali | J | 15,000 | $0.00 | $0.00 | filing |
| 2026-06-30 | Janku Filip· Chief Medical Officer | Sale | 5,407 | $24.50 | $132,471.50 | filing |
| 2026-06-30 | Janku Filip· Chief Medical Officer | Option exercise | 5,407 | $13.41 | $72,507.87 | filing |
| 2026-06-29 | Manning Anthony M. | Sale | 10,000 | $23.11 | $231,100.00 | filing |
| 2026-06-29 | Janku Filip· Chief Medical Officer | Sale | 6,000 | $22.95 | $137,700.00 | filing |
| 2026-06-29 | Janku Filip· Chief Medical Officer | Option exercise | 6,000 | $7.56 | $45,360.00 | filing |
| 2026-06-29 | Manning Anthony M. | Option exercise | 10,000 | $4.16 | $41,600.00 | filing |
| 2026-06-24 | Janku Filip· Chief Medical Officer | Sale | 30,000 | $21.42 | $642,681.00 | filing |
| 2026-06-24 | Janku Filip· Chief Medical Officer | Option exercise | 30,000 | $7.56 | $226,800.00 | filing |
| 2026-06-23 | Janku Filip· Chief Medical Officer | Sale | 11,845 | $20.22 | $239,522.48 | filing |
| 2026-06-23 | Townson Sharon· Chief Scientific Officer | Sale | 3,000 | $20.00 | $60,000.00 | filing |
| 2026-06-23 | Janku Filip· Chief Medical Officer | Option exercise | 6,000 | $7.56 | $45,360.00 | filing |
| 2026-06-23 | Champoux Jennifer· Chief Operating Officer | Sale | 2,175 | $20.00 | $43,500.00 | filing |
| 2026-06-23 | Townson Sharon· Chief Scientific Officer | Option exercise | 3,000 | $6.14 | $18,420.00 | filing |
| 2026-06-23 | Champoux Jennifer· Chief Operating Officer | Option exercise | 2,175 | $3.98 | $8,656.50 | filing |
| 2026-06-17 | Townson Sharon· Chief Scientific Officer | Sale | 3,000 | $19.00 | $57,000.00 | filing |
| 2026-06-17 | Champoux Jennifer· Chief Operating Officer | Sale | 2,176 | $19.00 | $41,344.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.